Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Kite Pharma (KITE) downgraded to Neutral from Buy at Citi with analyst Robyn Karnauskas saying this week's rally on the "strong data" price a lot of value into the shares. The analyst expects approval of axicabtagene and estimates worldwide peak sales of $1.7B, but sees little share upside from the pipeline in the near-term. She raised her price target for Kite shares to $87 from $62. 2. Apache (APA) downgraded to Underweight from Equal Weight at Barclays with analyst Thomas Driscoll saying he expects the company's 2018 oil volumes to fall below 2016 levels. He cut his price target for the shares to $50 from $56. 3. American Eagle (AEO) downgraded to Neutral from Buy at BofA/Merrill with analyst Stephen Albert citing disappointing first quarter comparable-store sales guidance. 4. TripAdvisor (TRIP) downgraded to Neutral from Overweight at Piper Jaffray with analyst Michael Olson saying estimates may move lower as the company potentially increases investment in re-education. Olson thinks TripAdvisor shares may be range-bound through the remainder of the year and he lowered his price target for the stock to $47 from $60. 5. Pacira (PCRX) downgraded to Sell from Neutral at Janney Capital with analyst Ken Trbovich stating that its guidance suggests no meaningful change in the outlook for Exparel sales this year. While the company also announced positive results from its Phase 4 study of Exparel in total knee replacement surgery, it may take "years" for the company to fully exploit this commercially, said Trbovich, who raised his fair value estimate on the stock to $38 from $34. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.